依曲康唑耐药烟曲霉致慢性空洞性肺曲霉病 1 例：Hmg1 基因 E306K 新突变
Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1.
机构信息
Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv Universitygrid.12136.37, Tel Aviv, Israel.
Department of Dermatology and Venerology, Peking University First Hospitalgrid.411472.5, National Clinical Research Center for Skin and Immune Diseases, Research Center for Medical Mycology, Peking University, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
出版信息
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0108921. doi: 10.1128/AAC.01089-21. Epub 2021 Jul 19.
Abstract
Triazole resistance in the pathogenic mold Aspergillus fumigatus has increased worldwide, posing a growing therapeutic challenge. Recently, mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase gene () have been associated with triazole resistance. Here, we describe a novel E306K triazole resistance-conferring mutation in the HMG-CoA reductase gene from an Israeli patient with chronic cavitary pulmonary aspergillosis (CCPA).
摘要
曲霉菌种中的致病真菌烟曲霉对三唑类药物的耐药性在全球范围内不断增加，这对治疗构成了日益严峻的挑战。最近，3-羟-3-甲基戊二酰基辅酶 A（HMG-CoA）还原酶基因（）中的突变与三唑类药物耐药性有关。在这里，我们描述了一位患有慢性空洞性肺曲霉病（CCPA）的以色列患者的 HMG-CoA 还原酶基因中的一种新型 E306K 三唑类耐药突变。
相似文献
1
Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0108921. doi: 10.1128/AAC.01089-21. Epub 2021 Jul 19.
2
Emergence of W272C Substitution in Hmg1 in a Triazole-Resistant Isolate of Aspergillus fumigatus from a Chinese Patient with Chronic Cavitary Pulmonary Aspergillosis.
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0026321. doi: 10.1128/AAC.00263-21.
3
Mutations in , Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus.
mBio. 2019 Apr 2;10(2):e00437-19. doi: 10.1128/mBio.00437-19.
4
Hmg1 mutations in Aspergillus fumigatus and their contribution to triazole susceptibility.
Med Mycol. 2021 Oct 4;59(10):980-984. doi: 10.1093/mmy/myab026.
5
High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.
Med Mycol. 2021 Apr 6;59(4):327-334. doi: 10.1093/mmy/myaa052.
6
and Mutations Are Drivers of -Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate.
Microbiol Spectr. 2023 Jun 15;11(3):e0518822. doi: 10.1128/spectrum.05188-22. Epub 2023 May 4.
7
Genomic perspective of triazole resistance in clinical and environmental Aspergillus fumigatus isolates without cyp51A mutations.
Fungal Genet Biol. 2019 Nov;132:103265. doi: 10.1016/j.fgb.2019.103265. Epub 2019 Aug 26.
8
A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1.
Nat Commun. 2024 Apr 29;15(1):3642. doi: 10.1038/s41467-024-48029-2.
9
Emergence of azole resistant- infections during STAT3-deficiency.
J Med Microbiol. 2020 Jun;69(6):844-849. doi: 10.1099/jmm.0.001200.
10
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia.
Rev Iberoam Micol. 2013 Jan 3;30(1):64-8. doi: 10.1016/j.riam.2012.09.002. Epub 2012 Sep 15.
引用本文的文献
1
A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1.
Nat Commun. 2024 Apr 29;15(1):3642. doi: 10.1038/s41467-024-48029-2.
2
and Mutations Are Drivers of -Independent Pan-Triazole Resistance in an Aspergillus fumigatus Clinical Isolate.
Microbiol Spectr. 2023 Jun 15;11(3):e0518822. doi: 10.1128/spectrum.05188-22. Epub 2023 May 4.
3
Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections.
Pathogens. 2023 Feb 10;12(2):293. doi: 10.3390/pathogens12020293.
4
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.
J Antimicrob Chemother. 2022 Jul 28;77(8):2053-2073. doi: 10.1093/jac/dkac161.
5
Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in ?
Molecules. 2021 Oct 1;26(19):5975. doi: 10.3390/molecules26195975.
本文引用的文献
1
Hmg1 mutations in Aspergillus fumigatus and their contribution to triazole susceptibility.
Med Mycol. 2021 Oct 4;59(10):980-984. doi: 10.1093/mmy/myab026.
2
Emergence of W272C Substitution in Hmg1 in a Triazole-Resistant Isolate of Aspergillus fumigatus from a Chinese Patient with Chronic Cavitary Pulmonary Aspergillosis.
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0026321. doi: 10.1128/AAC.00263-21.
3
Gene Mutation Prevalence in Triazole-Resistant Clinical Isolates.
J Fungi (Basel). 2020 Oct 16;6(4):227. doi: 10.3390/jof6040227.
4
Mechanisms of triazole resistance in Aspergillus fumigatus.
Environ Microbiol. 2020 Dec;22(12):4934-4952. doi: 10.1111/1462-2920.15274. Epub 2020 Oct 21.
5
High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.
Med Mycol. 2021 Apr 6;59(4):327-334. doi: 10.1093/mmy/myaa052.
6
Multicenter Study of Azole-Resistant Aspergillus fumigatus Clinical Isolates, Taiwan.
Emerg Infect Dis. 2020 Apr;26(4):804-806. doi: 10.3201/eid2604.190840.
7
Aspergillus fumigatus and Aspergillosis in 2019.
Clin Microbiol Rev. 2019 Nov 13;33(1). doi: 10.1128/CMR.00140-18. Print 2019 Dec 18.
8
Genomic perspective of triazole resistance in clinical and environmental Aspergillus fumigatus isolates without cyp51A mutations.
Fungal Genet Biol. 2019 Nov;132:103265. doi: 10.1016/j.fgb.2019.103265. Epub 2019 Aug 26.
9
Mutations in , Challenging the Paradigm of Clinical Triazole Resistance in Aspergillus fumigatus.
mBio. 2019 Apr 2;10(2):e00437-19. doi: 10.1128/mBio.00437-19.
10
Non-cyp51A Azole-Resistant Aspergillus fumigatus Isolates with Mutation in HMG-CoA Reductase.
Emerg Infect Dis. 2018 Oct;24(10):1889-1897. doi: 10.3201/eid2410.180730.
Zotero 插件